Message #13 From:
NewsBot Date: December 6, 2006 10:50:00 AM
GLIF News Grant Life Sciences hires Kim Liao as Director of Asian Business Development
LOS ANGELES--(BUSINESS WIRE)--Grant Life Sciences (‘Grant’)
Inc. (OTC BB: GLIF) announced today that it has hired Mr. Kim Liao as
director of Asian business development, effective immediately.
“We are extremely pleased to have such an
accomplished industry executive as Kim Liao join Grant Life Sciences,
particularly in light of his significant ‘hands
on’ experience in the markets of Taiwan, China
and Singapore,” said Hun-Chi Lin, Ph.D., Grant’s
President and Chief Scientist. “Certainly, Kim
will play a key role in executing Grant’s new
corporate strategy: (1) acquire new products and technologies via
in-licensing activities; (2) out-license products for further
development and sales; and (3) drive sales through our
established marketing channels. Kim will oversee development of Grant’s
expansion into Asia, including the structuring of clinical trials for
our HPV-DNA tests at United Clinical Lab (the largest reference lab in
Taiwan} and National Taiwan University’s
Medical Center. In short, Kim will be spearheading the commercialization
of Grant’s products from clinical acceptance
to sales in new, key Asian markets.”
Between 1995 and 2006, Kim Liao held a variety of executive positions
with increasing responsibilities in the areas of sales, product
management and general management with Abbott Laboratories Services Corp.’s
Diagnostics Division, Medtronic Taiwan and Becton Dickinson Worldwide
(Taiwan). He holds a master’s degree in
microbiology from California State University (Fullerton) as well as
numerous certifications in pathology and clinical laboratory technology.
About Grant Life Sciences Inc.
Grant Life Sciences, a development stage company, engages in research,
development, marketing, and sale of diagnostic kits for the screening,
monitoring, and diagnosis of diseases with emphasis on women’s
health, infectious diseases, and cancers.
Forward-Looking Safe Harbor Statement
With the exception of historical information, the matters discussed in
this press release are "forward-looking statements" that involve a
number of risks and uncertainties. The actual future results of Grant
Life Sciences could differ significantly from those statements. Factors
that could cause actual results to differ materially include risks and
uncertainties such as the inability to finance the company's operations
or expansion, inability to hire and retain qualified personnel, changes
in the general economic climate, including rising interest rates and
unanticipated events such as terrorist activities, results of clinical
trials, and market acceptance of the Company's products. In some cases,
"forward-looking statements" can be identified by terminology such as
"may," "will," "should," "expect," "plan," "anticipate," "believe,"
"estimate," "predict," "potential" or "continue," or other comparable
terminology. Although Grant Life Sciences believes that the expectations
reflected in the "forward-looking" statements are reasonable, such
statements should not be regarded as a representation by the Company, or
any other person, that such "forward-looking statements" will be
achieved. Grant Life Sciences undertakes no duty to update any of the
"forward-looking statements," whether as a result of new information,
future events or otherwise. In light of the foregoing, readers are
cautioned not to place undue reliance on such "forward-looking
statements." For further risk factors associated with our Company,
review our SEC filings.
